HRP20241214T1 - Indukcija male molekule trail genoma u normalnim i tumorskim a stanicama kao terapija protiv raka - Google Patents
Indukcija male molekule trail genoma u normalnim i tumorskim a stanicama kao terapija protiv raka Download PDFInfo
- Publication number
- HRP20241214T1 HRP20241214T1 HRP20241214TT HRP20241214T HRP20241214T1 HR P20241214 T1 HRP20241214 T1 HR P20241214T1 HR P20241214T T HRP20241214T T HR P20241214TT HR P20241214 T HRP20241214 T HR P20241214T HR P20241214 T1 HRP20241214 T1 HR P20241214T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutical composition
- use according
- cancer
- agent
- subject
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 2
- 201000011510 cancer Diseases 0.000 title 1
- 230000006698 induction Effects 0.000 title 1
- 150000003384 small molecules Chemical class 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- 238000000034 method Methods 0.000 claims 5
- 239000002246 antineoplastic agent Substances 0.000 claims 3
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 2
- 239000012472 biological sample Substances 0.000 claims 2
- 201000007455 central nervous system cancer Diseases 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 206010018338 Glioma Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 229940121849 Mitotic inhibitor Drugs 0.000 claims 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
- 201000010133 Oligodendroglioma Diseases 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims 1
- 102000046283 TNF-Related Apoptosis-Inducing Ligand Human genes 0.000 claims 1
- 101710097160 Tumor necrosis factor ligand superfamily member 10 Proteins 0.000 claims 1
- 229960000397 bevacizumab Drugs 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 229960003668 docetaxel Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000011156 evaluation Methods 0.000 claims 1
- 238000001361 intraarterial administration Methods 0.000 claims 1
- 238000000185 intracerebroventricular administration Methods 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000007913 intrathecal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 206010027191 meningioma Diseases 0.000 claims 1
- 208000023833 nerve sheath neoplasm Diseases 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- 201000005528 peripheral nervous system neoplasm Diseases 0.000 claims 1
- 210000002381 plasma Anatomy 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- RSAQARAFWMUYLL-UHFFFAOYSA-N tic-10 Chemical compound CC1=CC=CC=C1CN1C(CCN(CC=2C=CC=CC=2)C2)=C2C(=O)N2CCN=C21 RSAQARAFWMUYLL-UHFFFAOYSA-N 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161480743P | 2011-04-29 | 2011-04-29 | |
| EP20152317.2A EP3679934B1 (en) | 2011-04-29 | 2012-04-30 | Small molecule trail gene induction by normal and tumor cells as an anticancer therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20241214T1 true HRP20241214T1 (hr) | 2024-11-22 |
Family
ID=47068061
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20241214TT HRP20241214T1 (hr) | 2011-04-29 | 2012-04-30 | Indukcija male molekule trail genoma u normalnim i tumorskim a stanicama kao terapija protiv raka |
| HRP20200636TT HRP20200636T1 (hr) | 2011-04-29 | 2012-04-30 | Indukcija male molekule trail genoma u normalnim i tumorskim stanicama kao antikancerogena terapija |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20200636TT HRP20200636T1 (hr) | 2011-04-29 | 2012-04-30 | Indukcija male molekule trail genoma u normalnim i tumorskim stanicama kao antikancerogena terapija |
Country Status (18)
| Country | Link |
|---|---|
| US (9) | US8673923B2 (enExample) |
| EP (3) | EP4335511B1 (enExample) |
| JP (7) | JP6132833B2 (enExample) |
| CA (1) | CA2832342C (enExample) |
| CY (1) | CY1123010T1 (enExample) |
| DK (2) | DK3679934T3 (enExample) |
| ES (2) | ES2992934T3 (enExample) |
| FI (1) | FI3679934T3 (enExample) |
| HR (2) | HRP20241214T1 (enExample) |
| HU (2) | HUE068623T2 (enExample) |
| LT (2) | LT3679934T (enExample) |
| MX (2) | MX365365B (enExample) |
| PL (2) | PL2701708T3 (enExample) |
| PT (2) | PT2701708T (enExample) |
| RS (2) | RS65813B1 (enExample) |
| SI (2) | SI2701708T1 (enExample) |
| SM (2) | SMT202400421T1 (enExample) |
| WO (1) | WO2012149546A2 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2701708T (pt) | 2011-04-29 | 2020-05-08 | Penn State Res Found | Indução de gene trail de moléculas pequenas através de células tumorais e normais como uma terapia anticancro |
| US10813630B2 (en) | 2011-08-09 | 2020-10-27 | Corquest Medical, Inc. | Closure system for atrial wall |
| US10307167B2 (en) | 2012-12-14 | 2019-06-04 | Corquest Medical, Inc. | Assembly and method for left atrial appendage occlusion |
| US10314594B2 (en) | 2012-12-14 | 2019-06-11 | Corquest Medical, Inc. | Assembly and method for left atrial appendage occlusion |
| US20140142689A1 (en) | 2012-11-21 | 2014-05-22 | Didier De Canniere | Device and method of treating heart valve malfunction |
| RS59013B1 (sr) * | 2013-03-13 | 2019-08-30 | Oncoceutics Inc | 7-benzil-10-(2-metilbenzil)-2,6,7,8,9,10-heksahidroimidazo[1,2-a]pirido[4,3-d]pirimidin-5(3h)-on za upotrebu u lečenju kancera |
| US9688679B2 (en) | 2013-03-13 | 2017-06-27 | Oncoceutics, Inc. | 7-benzyl-4-(methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-A]pyrido[3,4-E]pyrimidin-5 (1H)-one, salts thereof and methods of using the same in combination therapy |
| US9376437B2 (en) | 2013-03-13 | 2016-06-28 | Oncoceutics, Inc | 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy |
| WO2015073072A1 (en) * | 2013-11-15 | 2015-05-21 | Oncoceutics, Inc. | 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one |
| HUE043291T2 (hu) * | 2013-11-15 | 2019-08-28 | Oncoceutics Inc | 7-benzil-4-(2-metilbenzil)-2,4,6,7,8,9-hexahidroimidazo[1,2-a] pirido[3,4-e]pirimidin-5(lH)-on, sói és alkalmazási eljárások |
| US9566443B2 (en) | 2013-11-26 | 2017-02-14 | Corquest Medical, Inc. | System for treating heart valve malfunction including mitral regurgitation |
| WO2015138638A1 (en) | 2014-03-11 | 2015-09-17 | Theraly Pharmaceuticals, Inc. | Long acting trail receptor agonists for treatment of autoimmune diseases |
| US10239877B2 (en) | 2014-03-31 | 2019-03-26 | The Scripps Research Institute | Pharmacophore for trail induction |
| US10842626B2 (en) | 2014-12-09 | 2020-11-24 | Didier De Canniere | Intracardiac device to correct mitral regurgitation |
| SMT202500087T1 (it) | 2015-01-30 | 2025-03-12 | Oncoceutics Inc | Derivati di 7-benzil-4-(2-metilbenzil)-2,4,6,7,8,9-esaidroimidazo[1,2-a]pirido[3,4-e]pirimidin-5(1h)-one, loro sali e loro uso in terapia |
| AU2016243612A1 (en) | 2015-03-31 | 2017-10-12 | The University Of North Carolina At Chapel Hill | Delivery vehicles for stem cells and uses thereof |
| CN104860948B (zh) | 2015-05-15 | 2017-09-26 | 南京盖特医药技术有限公司 | 咪唑并嘧啶酮类化合物及其制备方法和应用 |
| US11007251B2 (en) | 2015-12-17 | 2021-05-18 | The Johns Hopkins University | Ameliorating systemic sclerosis with death receptor agonists |
| BR112018015590A2 (pt) | 2016-01-29 | 2019-10-01 | Oncoceutics Inc | modulação de receptor acoplado à proteína g (gpcr) por imipridonas |
| CN109195620B (zh) | 2016-04-07 | 2022-06-28 | 约翰霍普金斯大学 | 用死亡受体激动剂治疗胰腺炎和疼痛的组合物和方法 |
| US10172862B2 (en) | 2017-01-30 | 2019-01-08 | Oncoceutics, Inc. | Imipridones for gliomas |
| US11767353B2 (en) | 2020-06-05 | 2023-09-26 | Theraly Fibrosis, Inc. | Trail compositions with reduced immunogenicity |
| CA3263675A1 (en) | 2022-08-05 | 2024-02-08 | Chimerix, Inc. | Pharmaceutical compositions and their uses for the treatment of glioma |
| WO2024102447A1 (en) * | 2022-11-10 | 2024-05-16 | Emory University | Uses of hydroimidazopyridopyrimidinone derivatives for managing aneurysms or other vascular conditions or diseases |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA105008A (en) | 1907-02-06 | 1907-04-30 | Charles B. Grimshaw | Self-closing valve |
| DE2150062A1 (de) * | 1971-10-07 | 1973-04-12 | Boehringer Sohn Ingelheim | Imidazo- eckige klammer auf 1,2-a eckige klammer zu -pyrido- eckige klammer auf 4,3-d eckige klammer zu -pyrimidine, deren saeureadditionssalze und verfahren zu deren herstellung |
| GB9407386D0 (en) | 1994-04-14 | 1994-06-08 | Smithkline Beecham Plc | Pharmaceutical formulation |
| US5648097A (en) | 1995-10-04 | 1997-07-15 | Biotek, Inc. | Calcium mineral-based microparticles and method for the production thereof |
| US6391336B1 (en) | 1997-09-22 | 2002-05-21 | Royer Biomedical, Inc. | Inorganic-polymer complexes for the controlled release of compounds including medicinals |
| ES2357225T3 (es) | 2001-11-01 | 2011-04-20 | Uab Research Foundation | Combinaciones de anticuerpos anti-dr5 y anticuerpos anti-dr4 y otros agentes terapéuticos. |
| AU2002367172A1 (en) | 2001-12-21 | 2003-07-15 | Bayer Pharmaceuticals Corporation | 2,4-diamino-pyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents |
| CN101336300A (zh) * | 2005-12-16 | 2008-12-31 | 健泰科生物技术公司 | 神经胶质瘤的诊断、预后和治疗方法 |
| US8084027B2 (en) * | 2006-02-10 | 2011-12-27 | Nerviano Medical Sciences S.R.L. | Combinations comprising a CDK inhibitor and a growth factor antibody or anti-mitotic |
| CA2656393A1 (en) | 2006-06-30 | 2008-01-10 | Schering Corporation | Method of using substituted piperidines that increase p53 activity |
| US20110129467A1 (en) * | 2008-07-24 | 2011-06-02 | Nerviano Medical Sciences S.R.L. | Therapeutic combination comprising an aurora kinase inhibitor and antiproliferative agents |
| CA2766322A1 (en) * | 2009-06-24 | 2010-12-29 | Stephen Evans-Freke | Methods of using corticotropin-releasing factor for the treatment of cancer |
| PT2701708T (pt) | 2011-04-29 | 2020-05-08 | Penn State Res Found | Indução de gene trail de moléculas pequenas através de células tumorais e normais como uma terapia anticancro |
| RS59013B1 (sr) | 2013-03-13 | 2019-08-30 | Oncoceutics Inc | 7-benzil-10-(2-metilbenzil)-2,6,7,8,9,10-heksahidroimidazo[1,2-a]pirido[4,3-d]pirimidin-5(3h)-on za upotrebu u lečenju kancera |
-
2012
- 2012-04-30 PT PT127760734T patent/PT2701708T/pt unknown
- 2012-04-30 PT PT201523172T patent/PT3679934T/pt unknown
- 2012-04-30 RS RS20240842A patent/RS65813B1/sr unknown
- 2012-04-30 CA CA2832342A patent/CA2832342C/en active Active
- 2012-04-30 EP EP23206770.2A patent/EP4335511B1/en active Active
- 2012-04-30 SI SI201231766T patent/SI2701708T1/sl unknown
- 2012-04-30 FI FIEP20152317.2T patent/FI3679934T3/fi active
- 2012-04-30 SI SI201232069T patent/SI3679934T1/sl unknown
- 2012-04-30 HU HUE20152317A patent/HUE068623T2/hu unknown
- 2012-04-30 LT LTEP20152317.2T patent/LT3679934T/lt unknown
- 2012-04-30 EP EP12776073.4A patent/EP2701708B1/en active Active
- 2012-04-30 LT LTEP12776073.4T patent/LT2701708T/lt unknown
- 2012-04-30 MX MX2013012346A patent/MX365365B/es active IP Right Grant
- 2012-04-30 HU HUE12776073A patent/HUE049207T2/hu unknown
- 2012-04-30 DK DK20152317.2T patent/DK3679934T3/da active
- 2012-04-30 US US13/459,775 patent/US8673923B2/en not_active Ceased
- 2012-04-30 SM SM20240421T patent/SMT202400421T1/it unknown
- 2012-04-30 HR HRP20241214TT patent/HRP20241214T1/hr unknown
- 2012-04-30 RS RS20200454A patent/RS60186B1/sr unknown
- 2012-04-30 ES ES20152317T patent/ES2992934T3/es active Active
- 2012-04-30 SM SM20200272T patent/SMT202000272T1/it unknown
- 2012-04-30 MX MX2019006379A patent/MX379539B/es unknown
- 2012-04-30 WO PCT/US2012/035831 patent/WO2012149546A2/en not_active Ceased
- 2012-04-30 DK DK12776073.4T patent/DK2701708T3/da active
- 2012-04-30 PL PL12776073T patent/PL2701708T3/pl unknown
- 2012-04-30 ES ES12776073T patent/ES2786033T3/es active Active
- 2012-04-30 JP JP2014508181A patent/JP6132833B2/ja active Active
- 2012-04-30 HR HRP20200636TT patent/HRP20200636T1/hr unknown
- 2012-04-30 PL PL20152317.2T patent/PL3679934T3/pl unknown
- 2012-04-30 EP EP20152317.2A patent/EP3679934B1/en active Active
-
2014
- 2014-02-27 US US14/192,329 patent/US9061032B2/en active Active
- 2014-07-22 US US14/338,055 patent/US9072744B1/en active Active
-
2015
- 2015-06-08 US US14/733,740 patent/US9452165B2/en active Active
- 2015-09-17 US US14/857,418 patent/USRE46290E1/en active Active
-
2016
- 2016-07-20 JP JP2016142086A patent/JP2016199580A/ja not_active Withdrawn
- 2016-09-19 US US15/269,114 patent/US9629842B2/en active Active
-
2017
- 2017-04-23 US US15/494,515 patent/US20170224690A1/en not_active Abandoned
-
2018
- 2018-11-08 JP JP2018210558A patent/JP2019019145A/ja not_active Withdrawn
-
2020
- 2020-04-14 CY CY20201100350T patent/CY1123010T1/el unknown
-
2021
- 2021-09-16 JP JP2021151110A patent/JP2021185210A/ja not_active Withdrawn
-
2022
- 2022-03-21 US US17/655,646 patent/US12036223B2/en active Active
-
2023
- 2023-03-06 JP JP2023033777A patent/JP7600286B2/ja active Active
-
2024
- 2024-02-27 JP JP2024027432A patent/JP2024051080A/ja active Pending
- 2024-06-12 US US18/740,833 patent/US20240415841A1/en active Pending
-
2025
- 2025-08-08 JP JP2025133453A patent/JP2025159099A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20241214T1 (hr) | Indukcija male molekule trail genoma u normalnim i tumorskim a stanicama kao terapija protiv raka | |
| US9242000B2 (en) | Micro-RNAs and micro-RNA inhibitors to modulate blood vessel growth, patterning, tumor growth and malignant disease and method for making and using them | |
| He et al. | MicroRNA-101 sensitizes hepatocellular carcinoma cells to doxorubicin-induced apoptosis via targeting Mcl-1 | |
| JP2021500349A5 (enExample) | ||
| Zhao et al. | miR-630 functions as a tumor oncogene in renal cell carcinoma | |
| BR112013025549A2 (pt) | sais de 2,3-hidroimidazo[1,2-c]quinazolina substituídos | |
| RU2014119150A (ru) | Модулирование некоторых тирозинкиназ | |
| NZ723271A (en) | Fused imidazole derivatives useful as ido inhibitors | |
| JP2006503919A5 (enExample) | ||
| JP2014526456A5 (enExample) | ||
| JP2016520528A5 (enExample) | ||
| JP2016519076A (ja) | マイクロｒｎａ及びｅｇｆｒ−ｔｋｉ阻害剤を利用する癌の併用処置 | |
| WO2008109432A3 (en) | Therapeutic targeting of interleukins using sirna in neutral liposomes | |
| Jiang et al. | Synergistic effects of Endostar combined with β-elemene on malignant ascites in a mouse model | |
| JP2015501645A5 (enExample) | ||
| JP2014530181A5 (enExample) | ||
| CA3065803A1 (en) | Biomarkers and patient selection strategies | |
| Yu et al. | Synergistic effects of combined platelet-activating factor receptor and epidermal growth factor receptor targeting in ovarian cancer cells | |
| WO2022188491A1 (zh) | 一种肿瘤化疗药物组合物 | |
| JP2008540364A5 (enExample) | ||
| Bocci et al. | The possible role of chemotherapy in antiangiogenic drug resistance | |
| JP2015514796A5 (enExample) | ||
| Zhang et al. | Resistance to cetuximab in EGFR-overexpressing esophageal squamous cell carcinoma xenografts due to FGFR2 amplification and overexpression | |
| RU2019134769A (ru) | Композиции для лечения резистентных к лекарственным средствам опухолей и способы их применения | |
| US20170079979A1 (en) | Therapy for solid tumors |